Literature DB >> 10400891

Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study.

Y Minabe1, K Matsuno, C R Ashby.   

Abstract

In this study, we examined the effect of the acute and repeated administration of the selective sigma (sigma)1 receptor agonist 1-(3, 4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) on the number and firing pattern of spontaneously active dopamine (DA) neurons in substantia nigra pars compacta (SNC) and ventral tegmental area (VTA) in anesthetized, male Sprague-Dawley rats. This was accomplished using the technique of in vivo extracellular single unit recording. The intravenous administration of SA4503 (0.01-1.28 mg/kg) did not significantly alter the firing rate or pattern of spontaneously active DA neurons in either the SNC or VTA. A single injection of either 0.1 or 0.3 mg/kg i.p. of SA4503 did not alter the number of spontaneously active SNC and VTA DA neurons. In contrast, a single injection of 1 mg/kg i.p. of SA4503 produced a significant decrease and increase in the number of spontaneously active SNC and VTA DA neurons, respectively. Overall, the firing pattern parameters of spontaneously active SNC DA neurons were altered more significantly than those of spontaneously active VTA DA neurons following the acute administration of SA4503. The repeated administration (one injection per day for 21 days) of 0.3 and 1 mg/kg i.p. of SA4503 produced a significant increase in the number of spontaneously active VTA DA neurons. In addition, the repeated administration of SA4503 produced a greater alteration of the firing pattern of spontaneously active VTA compared to SNC DA neurons. Our results suggest that the administration of SA4503 significantly alters the activity of spontaneously active midbrain DA neurons, particularly those in the VTA following repeated administration. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400891     DOI: 10.1002/(SICI)1098-2396(199908)33:2<129::AID-SYN3>3.0.CO;2-E

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  12 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

2.  Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats.

Authors:  Angelo Blasio; Marta Valenza; Malliga R Iyer; Kenner C Rice; Luca Steardo; T Hayashi; Pietro Cottone; Valentina Sabino
Journal:  Behav Brain Res       Date:  2015-04-04       Impact factor: 3.332

Review 3.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

4.  N-phenylpropyl-N'-substituted piperazines occupy sigma receptors and alter methamphetamine-induced hyperactivity in mice.

Authors:  Dennis K Miller; Eric S Park; Susan Z Lever; John R Lever
Journal:  Pharmacol Biochem Behav       Date:  2016-11-13       Impact factor: 3.533

5.  SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus.

Authors:  Kelli R Rodvelt; Susan Z Lever; John R Lever; Lucas R Blount; Kuo-Hsien Fan; Dennis K Miller
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

6.  Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis.

Authors:  Linda Garcés-Ramírez; Jennifer L Green; Takato Hiranita; Theresa A Kopajtic; Maddalena Mereu; Alexandra M Thomas; Christophe Mesangeau; Sanju Narayanan; Christopher R McCurdy; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2010-10-15       Impact factor: 13.382

Review 7.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Luca Steardo; George F Koob; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

9.  Ethanol and phencyclidine interact with respect to nucleus accumbens dopamine release: differential effects of administration order and pretreatment protocol.

Authors:  Chris Pickering; Pei Pei Chau; Bo Söderpalm; Mia Ericson
Journal:  Front Behav Neurosci       Date:  2010-06-10       Impact factor: 3.558

10.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.